Relationship Between Benralizumab Exposure and Efficacy for Patients with Severe Eosinophilic Asthma

Asthma

The association between blood eosinophil count and benralizumab efficacy for patients with severe, uncontrolled asthma: subanalyses of the Phase III SIROCCO and CALIMA studies

Curr Med Res Opin.

Goldman M, Hirsch I, Zangrilli JG, Newbold P, Xu X

doi: 10.1080/

RECOMMENDED

Asthma

Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma

Eur Respir J.

Bleecker ER, Wechsler ME, FitzGerald JM, Menzies-Gow A, Wu Y, Hirsch I, Goldman M, Newbold P, Zangrilli JG

doi: 10.1183/13993003.

Asthma

Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma

Ann Allergy Asthma Immunol.

Chipps BE, Newbold P, Hirsch I, Trudo F, Goldman M

doi: 10.1016/j.anai.2018.01.030.

RECOMMENDED

Asthma

Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial

Lancet Respir Med.

Busse WW, Bleecker ER, FitzGerald JM, Ferguson GT, Barker P, Sproule S, Olsson RF, Martin UJ, Goldman M; BORA study investigators

doi: 10.1016/S2213-2600

Asthma

Ability of Serum IgE Concentration to Predict Exacerbation Risk and Benralizumab Efficacy for Patients with Severe Eosinophilic Asthma

Adv Ther.

Jackson DJ, Humbert M, Hirsch I, Newbold P, Garcia Gil E

doi: 10.1007/s12325-019-01191-2.

Asthma

Efficacy and safety of benralizumab in patients with eosinophilic asthma: a meta-analysis of randomized placebo-controlled trials

Front Med.

Liu T, Wang F, Wang G, Mao H

doi: 10.1007/s11684-017-0565-0.

RECOMMENDED

Asthma

Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison

J Allergy Clin Immunol.

Busse W, Chupp G, Nagase H, Albers FC, Doyle S, Shen Q, Bratton DJ, Gunsoy NB

doi: 10.1016/j.jaci.2018.08.031.

Asthma

Reslizumab Compared with Benralizumab in Patients with Eosinophilic Asthma: A Systematic Literature Review and Network Meta-Analysis

J Allergy Clin Immunol Pract.

Casale TB, Pacou M, Mesana L, Farge G, Sun SX, Castro M

doi: 10.1016/j.jaip.2018.08.036.

Asthma

Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies

Lancet Respir Med.

FitzGerald JM, Bleecker ER, Menzies-Gow A, Zangrilli JG, Hirsch I, Metcalfe P, Newbold P, Goldman M

doi: 10.1016/

Related content

The association between blood eosinophil count and benralizumab efficacy for patients with severe, uncontrolled asthma: subanalyses of the Phase III SIROCCO and CALIMA studies

Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma

Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma

Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial

Ability of Serum IgE Concentration to Predict Exacerbation Risk and Benralizumab Efficacy for Patients with Severe Eosinophilic Asthma

Efficacy and safety of benralizumab in patients with eosinophilic asthma: a meta-analysis of randomized placebo-controlled trials

Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison

Reslizumab Compared with Benralizumab in Patients with Eosinophilic Asthma: A Systematic Literature Review and Network Meta-Analysis

Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies